BREAKING NEWS
No CM can remain absent for long, it’s against national interest: Delhi HC on Kejriwal
UGC-NET postponed to June 18 to avoid clash with UPSC prelims
Heatwave threat: Orange alert issued for 17 districts in Karnataka
PCB finalises Lahore, Karachi, Rawalpindi as venues for Champions Trophy
Include 4 hrs of physical activity, 8 hrs sleep in routine for optimal health, suggests study
Chhattisgarh: 9 killed, 23 injured as goods vehicle collides with truck in Bemetara district
Kharge authorised to decide Amethi, Raebareli candidates: Congress
Padubidri: Man thrashes bus driver in road rage incident
SC extends stay on proceedings in hate speech case against TN BJP chief K Annamalai
Focus on KL Rahul to prove himself ahead Indian team selection when LSG take on MI
Congress is planning religion-based quota, I will not let this happen: PM Modi at Karnataka rally
LS polls 2024: Setback for Congress in Indore — Party nominee Akshay Bam withdraws candidature
CET 2024: 50 questions to be dropped; no re-examination
T20 World Cup: NZ squad announced; Ravindra, Henry first-timers in Williamson-led team
This party wants to be voice of ‘mard’ in LS polls
Glenmark Pharma gets tentative nod from USFDA for cancer treatment drug
PTI, Dec 1, 2020, 1:50 PM IST
New Delhi: Drug major Glenmark Pharma on Tuesday said it has received tentative approval from the US health regulator for Axitinib tablets, used in the treatment of kidney cancer. The tentatively approved product is the generic version of Inlyta tablets of PF Prism CV.
Glenmark Pharmaceuticals Inc, USA has received tentative approval by the United States Food & Drug Administration (USFDA) for Axitinib tablets in the strength of 1 mg and 5 mg, the company said in a regulatory filing.
Quoting IQVIA sales data for the 12 months ending October 2020, Glenmark Pharma said the Inlyta Tablets, 1 mg and 5 mg market achieved annual sales of approximately USD 518.8 million.
Glenmark’s current portfolio consists of 166 products authorised for distribution in the US market and 45 ANDA’s pending approval with the USFDA.
Udayavani is now on Telegram. Click here to join our channel and stay updated with the latest news.
Top News
Related Articles More
ISRO releases ISSAR 2023 report on vulnerability of space assets to collisions
Private players will make space more accessible: ISRO chief
Study predicts accelerated warming of Indian ocean with catastrophic consequences
Space enthusiasts ask ISRO chief if agency can find water on moon
Deep-tech drives growing patenting patterns in India; highest filings in Tamil Nadu: Study
MUST WATCH
Latest Additions
ISRO releases ISSAR 2023 report on vulnerability of space assets to collisions
Hunasagi: MLA Bairati Basavaraj’s car overturned
No CM can remain absent for long, it’s against national interest: Delhi HC on Kejriwal
Cricket for the Blind: A Transformative Journey Empowering Visually Impaired Athletes
China lifts restrictions, gives all clear nod for Tesla cars as Musk lobbies hard in surprise visit to Beijing